Josep M. Llovet – 29 October 2007

Kayvan Roayaie, Sandy Feng – 29 October 2007 – Currently, liver transplantation is the optimal cure for hepatocellular cancer (HCC) limited to the liver.

James F. Trotter, Karen A. Wisniewski, Norah A. Terrault, James E. Everhart, Milan Kinkhabwala, Robert M. Weinrieb, Jeffrey H. Fair, Robert A. Fisher, Alan J. Koffron, Sammy Saab, Robert M. Merion, A2ALL Study Group – 29 October 2007 – The purpose of donor evaluation for adult‐to‐adult living donor liver transplantation (LDLT) is to discover medical conditions that could increase the donor postoperative risk of complications and to determine whether the donor can yield a suitable graft for the recipient.

Alex Rovira, Beatriz Mínguez, F. Xavier Aymerich, Carlos Jacas, Elena Huerga, Juan Córdoba, Juli Alonso – 29 October 2007 – Focal T2‐weighted white matter lesions (WML) on brain magnetic resonance imaging (MRI), mimicking those seen in cerebrovascular small‐vessel disease described in patients with persistent hepatic encephalopathy, decreased in volume with the improvement of hepatic encephalopathy. This outcome has been interpreted as a decrease in the edema that it is proposed to be involved in the pathogenesis of hepatic encephalopathy.

Teh‐Ia Huo, Jaw‐Ching Wu, Shou‐Dong Lee – 29 October 2007

Christoph R. Werner, Ulrich M. Lauer, Christoph P. Berg, Stephan Kaiser, Burkhard Ludescher, Oliver Luz, Ruth Ladurner, Michael Gregor, Florian Graepler – 29 October 2007

M. Rasool Aljabiri, Francesca Lodato, Andrew K. Burroughs – 29 October 2007

Christopher Paul Day – 29 October 2007 – Severe alcoholic steatohepatitis (ASH) is the major complication of advanced alcoholic liver disease (ALD) and has a high mortality even when treated with corticosteroids.

Robert M. Weinrieb, Michael R. Lucey – 29 October 2007 – Very little addiction treatment research has been done concerning smoking cessation, illicit drugs, or even alcohol abuse in liver transplant patients.

Giorgio Bedogni, Lucia Miglioli, Flora Masutti, Anna Castiglione, Lory Saveria Crocè, Claudio Tiribelli, Stefano Bellentani – 29 October 2007 – Using the general population of the Dionysos Study, we followed up 144 subjects without fatty liver (FL−) and 336 with fatty liver (FL+) for a median time of 8.5 years. All subjects had suspected liver disease (SLD) defined as altered liver enzymes, high mean corpuscular volume, or low platelet count in the absence of HBV and HCV infection. Ethanol intake was assessed using a food frequency questionnaire, and FL was diagnosed using ultrasonography.